CONTRIBUTORS

Aiuti, F. Viale dell'Universita, 37 Policlinico Umberto I 00161 - Rome, Italy

Albert i, S. Maria Negri Institute Milan, Italy

Appelboom, T. Department of Rheumatology Erasme Hospital, Universite Libre de Brauxelles, Brussels, Belguim

Azuma, I. Section of Chemistry, Institute of Immunological Science Hokkaido University Kita-Ku, Sapporo 060, Japan

Bach, J.F. ISERM U2S, Hopital Necker Paris, France

Bargelles i, A. Istituto di Chimica Biologica Universita di Genova Genova, Italy

Baudrihaye, N. ISERM U2S, Hopital Necker Paris, France

Bendinell i, M. Institute of Hygiene University of Pisa Pisa, Italy

435

436

Bernengo, M.G. Clinica Dermatologica University di Tarino Italy

Binaghi, R.A. Centre de Physiologie et d' Immunologie Cellulaires, ISERM U 104 Hopital Saint Antoine, Paris, France

Bocci, V. Instituto di Fis iologia Generale dell' Universita di Siena Siena, Italy

Borashi, D. Sclavo Research Center Siena, Italy

Bruschi, F. Centre de Physiologie et d' Immunologie Cellulaires, ISERM U 104 Hopital Saint Antoine, Paris, France

Businco, L. Departments of Clinical Immunology

and Pediatrics University of Rome Rome, Italy

Butler, R.C. Arlington Hospital Arlington, Virginia

Canonica, G.W. Istituto Scientifico Tumori Genova, Italy

Cengiarotti, L. Institute of Internal Medicine University of Cagliari Medical School Cagl iari, Italy

Cernetti, C. Istituto di Clinical Medica dell' Universita di Peragia, Italy

CONTRIBUTORS

CONTRIBUTORS

Chatenoud, L. ISERM U25, Hopital Necker Paris, France

Chessa, E. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Chkoff, N. ISERM U25, Hopital Necker Paris, France

Collet, H. Department of Immunology University Hospital, St. Pierre Free University of Brussels Brussels, Belguim

Corte, G. Istituto di Chimica Biologica Universita di Genova Genova, Italy

Dardenne, M. ISERM U25, Hopital Necker Par is, France

Daskal, V. Department of Medicine Baylor College of Medicine Houston, Texas

Davis, S. Istituto di Clinical Medica dell' Universita di Peragia, Italy

DeBruyn, C.H.M.M. Department of Human Genetics University of Nijmegen The Netherlands

Delespesse, G. Department of Immunology University Hospital, St. Pierre Free University of Brussels Brussels, Belguim

437

438

Del Giacco, G.S. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

De Simone, C. Clinica Malattie Infettine Universita degli Studi di Roma Roma, Italy

Di Tucci, A. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Dray, S.

CONTRIBUTORS

Department of Microbiology and Immunology Univeristy of Illinois at the Medical Center Chicago, Illinois

EI Ansary, M. Hopital E Herriot ISERM U 80 Lyon, France

Faurot, M.C. Hopital E Herriot ISERM U 80 Lyon, France

Fiorilli, M. Department of Clinical

Immunology University of Rome Rome, Italy

Fra, P. Clinica Dermatologica University di Tarino Italy

Friedman, H. Department of Microbiology and

Immunology University of South Florida College of Medicine Tampa, Florida

CONTRIBUTORS

Fudenberg, H.H. Department of Basic and Clinical

Immunology and Microbiology Medical University of South Carolina Charleston, South Carolina

Galli, M. Clinica Medica II and Clinica delle Malattie Infettine Universita di Milano Milano, Italy

Ginsberg, T. Newport Pharmaceuticals

International, Inc. Newport Beach, California

Grignani, F. Istituto di Clinical Medica dell' Universita di Peragia, Italy

Hadden, J.W. Memorial Sloan-Kettering Cancer Center New York, New York

Klein, A.S. Department of Life Sciences Bar-Ilan University Ramot - Gan, Israel

Klein, T. Department of Microbiology and

Immunology University of South Florida College of Medicine Tampa, Florida

Kreis, H. ISERM U25, Hopital Necker Paris, France

Kronke, M. Institut fur Medizinische Mikrobiolog ie der Johannes Gutenberg -Universitat Mainz, Mainz, West Germany

Lauriola, L. Departments of Pathology

and Histology Catholic University Rome, Italy

439

440

Lazzarin, A. Clinica Medica II and Clinica delle Malattie Infettine Universita' di Milano Milano, Italy

Lisa, F. Clinica Dermatologica University di Tarino Italy

Locci, F.

CONTRIBUTORS

Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Luini, W. Maria Negri Institute Milan, Italy

Maggiano, N. Departments of Pathology

and Histology Catholic University Rome, Italy

Mannick, J.A. Harvard Medical School Brigham and Women's Hospital Boston, Massachusetts

Marmont, A.M. Division of Hematology

and Clinical Immunology S. Martino Hospital Genova, Italy

Martelli, M.F. Istituto di Clinical Medica dell' Universita di Peragia, Italy

Mattioli, C.A. Department of Pathology Baylor College of Medicine Houston, Texas

Meloni, G. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

CONTRIBUTORS

Meregalli, M. Clinica Dermatologica University di Tarino Italy

Mokyr, M.B. Department of Immunology/Microbiology Rush Presbyterian - St. Luke's Medical Center Ch ic ago, Illino is

Montaldo, E. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Moretta, A. Instituto Scientifico di Medicina Interna Universtide Genova Genova, Italy

Moroni, M. Clinica Medica II and Clinica delle Malattie Infettiue Universita' di Milano Milano, Italy

Musiani, P. Departments of Pathology

and Histology Catholic University Rome, Italy

Nencioni, L. Sclavo Research Center Siena, Italy

Novelli, M. Clinica Dermatologica University di Tarino Italy

Paganelli, R. Cattedra di Immunologia Clinica Universita di Roma Rome, Italy

Pautasso, M. Institute of Internal Medicine University of Cagliari Medical School Cagl iari, Italy

441

442

Pfizenmaier, K. Institut fur Medizinische Mikrobiolog ie der Johannes Gutenberg -Universitat Mainz, Mainz, West Germany

Piantelli, M. Departments of Pathology

and Histology. Catholic University Rome, Italy

Piludu, G. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Piras, M.C. Institute of Internal Medicine University of Cagliari Medical School Cagliari, Italy

Pugnaloni, L. Clinica Malattie Infettine Universita degli Studi di Roma Roma, Italy

Quinti, 1. Departments of Clinical Immunology

and Pediatrics University of Rome Rome, Italy

Ramarli, D. Ludwig Institute for Cancer Research Epalinges, Lausanne

Rambott i, P. 1st ituto di Clinical Med ica dell' Universita di Peragia, Italy

Ranelletti, F.O. Departments of Pathology

and Histology Catholic University Rome, Italy

Richie, J.P. Harvard Medical School Brigham and Women's Hospital Boston, Massachusetts

CONTRIBUTORS

CONTRIBUTORS

Russo, G. Departments of Clinical Immunology

and Pediatrics University of Rome Rome, Italy

Seminara, R. Departments of Clinical Immunology

and Ped iatr ics University of Rome Rome, Italy

Shoham, J. The Institute of Oncology Chaim Sheba Medical Center Tel Hashomer, Israel

Sirianni, M.C. Departments of Clinical Immunology and

Pediatrics University of Rome Rome, Italy

Sir iann i, M. S . Cattedra di Immunologia Clinica Universita di Roma Rome, Italy

Sorice, F. Clinica Malattie Infettine Universita degli Studi di Roma Roma, Italy

Spinozz i, F. Istituto di Clinical Medica dell' Universita di Peragia, Italy

Spreafico, F. Instituti di Recerche Farmacologiche "Mario Negri", Milan, Italy

Steele, G.D. Harvard Medical School Brigham and Women's Hospital Boston, Massachusetts

Tagl iabue, A. Sclavo Research Center Siena, Italy

443

444 CONTRIBUTORS

Terman, D.S. Department of Microbiology and Immunology Baylor College of Medicine Houston, Texas

Touraine, J.L. Hopital E Herriot ISERM U 80 Lyon, France

Tovey, M.G. Institut de Recherches

Scientifiques Sur Ie Cancer Laboratory of Viral Oncology Villejuif, France

Tsang, K.Y. Department of Basic and Clinical

Immunology and Microbiology Medical University of South Carolina Charleston, South Carolina

Van Laarhoven, J.P.R.M. Department of Human Genetics University of Nijmegen The Netherlands

Vecchi, A. Instituti di Recerche Farmacologiche "Mari Negri", Milan, Italy

Velardi, A. Istituto di Clinical Medica dell' Universita di Peragia, Italy

Venturiello, S.M. Centre de Physiologie et d' Immunologie Cellulaires, ISERM U 104 Hopital Saint Antoine, Paris, France

Wagner, H. Institut fur Medizinische Mikrobiolog ie der Johannes Gutenberg -Universitat Mainz, Mainz, West Germany

Wang, B.S. Harvard Medical School Brigham and Women's Hospital Boston, Massachusetts

CONTRIBUTORS

Wilson, G.B. Department of Basic and Clinical

Immunology and Microbiology Med ical Univers ity of South Caro lina Charleston, South Carolina

Wybran, J. Department of Immunology and Hematology Erasme Hospital, Universite Libra de Bruxelles, Brussels, Belguim

Yamamura, Y. Osaka University Yamada-Oka, Suita, Osaka 565, Japan

Zanussi, C. Clinica Medica II and Clinica delle Malattie Infettine Universita' di Milano Milano, Italy

Zanzoglu, S. Clinica Malattie Infettine Universita degli Studi di Roma Roma, Italy

Zina, G. Clinica Dermatologica University di Tarino Italy

445

INDEX

N-Acetyl-muranyl-L-alanyl-d-iso­glutamine (MDP), 213, 254

Adenocarcinoma canine breast-, 229-247 characteristics, clinical,

listed, 232 human breast -, 229-247 protein A therapy of, 229-247

Adenosine and lymphocyte func­tion, 257-267

Adenosine de aminase, 258, 331 deficiency, 10

and lymphocyte dysfunction, 372

see EHNA Adenosine monophosphate, cyclic

(cAMP), 3 Adherence assay, 87 Adrenocorticoid hormone, 181 Ad riamy cin, 242 Aflatoxin, 324 Aleutian mink disease virus,

163 Alloantigen, 5, 285-288 Allogeneic response, 4 Allograft, renal, 399 Aluminum, 37 Amikacin, 116 Amphotericin B, 117 Anemia

aplastic, 430, 431 hypoplastic, congenital, 431

Antibiotics, see individual anti­biotic

Antibody, 210 auto -, 319 and cyclophosphamide, 349

Antibody (continued) monoclonal

and immunodeficiency, pri­mary, 4l3-425

and immunosuppressive agent, 402-405

MoAb, 413 against mononuclear cell,

human, 413-425 OKT, 2-3, 12, 13, 40, 48-52,

368, 399-406, 432 phenotype, 400-402 in renal transplant patient,

399-406 from streptococcus pyogenes,

368, 432 and T-cell, 399-406

and T-cell, 399-406 antigen la, 407-412 subset, 401

against thymulin, 37-38 Antithymocyte serum of rabbit,

350-354 Aplasia

adult pure red cell, 429, 431 eryhroplastic, infantile, 430

Arabinogalactan, 252 Arachidonic acid, 133 Arena virus, 184 Arthri tis

reactive, 371 and isoprinosine therapy, 371

rhematoid, 305 therapy, 370-372

Arylhydrocarbon hydroxylase, 323 Ascaris suum, 203

447

448

Ataxia-telangiectasia, 5, 9, 11, 12, 35, 411, 413, 417, ~

420, 422, 423 Atopy, 411 ATS, see Antithymocyte serum Autoantibody, anti-erythrocytic,

319 Autoimmunity, 185, 427-434

disorders, listed, 431

Bacillus Calmette-Guerin(BCG), 19, 212, 249, 296, 297

in cancer therapy, 249 Bacteria

antigen as immunomodulator, 209-228

Gram-negative, 213-215 Bordetella pertussis~ 215 endotoxin, 213, 220 enterotoxin, 214 Escherichia coli~ 214, 215 Listeria monocytogenes~ 338,

366 Serratia marcescens~ 215,

216 Vibrio cholerae~ 214

Gram-positive, 211-213 Corynebacterium parvum~ 213 Mycobacterium sp., 212 Nocardia rubra~ 250 pneumococci, 212 staphylococci, 211 streptococci, 211-212, 216,

368, 432 immune response

afferent arm, 210 efferent arm

lipopolysaccharide, 213, 215-222, 258, 295, 319, 333, 334, 338

lipoteichoic acid, 215-225, see Teichoic acid

immunostimulation by, 217 see individual species

Bacteriophage T2, 85 Bare lymphocyte syndrome, 7 B-cell, see Lymphocyte B-cell BCG, see Bactillus Calmette-

Guerin

INDEX

1,2-Benzisothiazid-3-(2H)-one-l, I-dioxide, see Saccharin

Benzypyrene tumor, 89 Bestatin, 250

and cancer therapy, 253-254 B-lymphocyte, see Lymphocyte B-

cell Bone marrow cell, 1-3 Bordetella pertussis toxin, 215 Breast cancer, 229-247, 367 Bronchitis, chronic, 343, 367 Burn patient, 388

methisoprinol therapy, 388

Cancer bestatin therapy, 153-154 immunotherapy in Japan, 249-256 therapy by Corynebacterium par-

vum~ 249 thymostimulin, 17-33 and thymus gland, 18 see individual cancers and tumors,

Carcinoma Candida sp., 106-112, 323, 367

C. albicans extract, 72, 78 Candidiasis

and amphotericin B therapy, 117 chronic mucocutaneous, 110, 117 DLE therapy, 117

Carcinoma ductal cell -, 240 mammary -, 89

Cell bone marrow, 1-3

and immunodeficiency disease, 5-7

epithelia thymic, 1-8 and human T-lymphocyte, 1-8

-mediated immunity(CMI), 115, 210

thymic epithelial, 1-8 -wall skeleton of Noeardia ruhra~

250 Chediak-Higashi syndrome, 422 Chelex-lOO, 36, 37 Chemotaxis

of eosinophil, 378, 382 of polymorphonuclear neutrophil,

338

INDEX

1-(2-Chloroethyl)-3-cyclohexyl-l­nitrosourea(CCNU), 19-22

Cholera toxin, 214 Choriomeningitis virus, lympho­

cytic, Bee MP virus Cirrhosis, biliary, primary, 411 Clq enzyme-immunoabsorbent assay

(Clq-ELISA), 71, 79 CMI, see Cell-mediated immunity Collodion-charcoal matrix, 230 Complement, 210 Concanavalin A, 43, 258, 295,

296, 319, 333, 334, 336, 338, 341

Contraceptive drugs, listed, 319 Coridus versicolor, Bee Krestin Corticosteroid, 400 Corynebacterium parvum, 213

in cancer therapy, 249 and interferon, 213 and natural killer cell, 213

Coxsackie virus, 163 strain B3 in mouse, 181

Creatinine in serum, 399 CVH, see Hypogammaglobulinemia,

common variable CY, see Cyclophosphamide Cycloheximide, 365 Cyclophosphamide, 232, 242, 318,

349-361 and antibody production, 349 and antitumor immunity, 349 and immunomodulation, 349-361 and tumor eradication, 349-361

Cyclosporin A, 293-302 from Cylindrocarpon lucidum,

293 immunosuppressive, 293 and lymphocyte, 294 and spleen cell, murine, 295 from Trichoderma polysporum,

293 Cylindrocarpon lucidum, 293

cyclosporin A formation, 293-302

Cytofluorometry, 3 Cytokine, 131 Cytolysis, lymphocyte-mediated,

94, 98 Cytomegalovirus, 106, 109, 163,

183, 185

Cytomegalovirus, (continued) congenital, 108

449

isoprinosine therapy, 370 Cytosine arabinoside, 250, 252 Cytotoxic index, 91, 96 Cytotoxicity, 4, 141, 210, 341,

356, 366 adherence assay, 87 antibody-dependent, 375 assay, 377

adherence assay, 87 1 mphocyte-mediated, 87, 91,

96 T-cell-mediated, 18, 183,

340 of lymphokine, 298 of natural killer cell, 299 and RNA, 86-87 of splenocyte, 92, 93 T-cell mediated, see Lympho­

cyte above against tumor cell, 298-299

Daunorub icin, 318 Dengue virus, 183 Deoxyadenosine and lymphocyte

function, 257-267 Deoxyribonucleic acid(DNA) syn-

thesis, assay of, 259 Dermatophytin, 106 Dexamethasone, 270-274 DiGeorge syndrome, 1, 5, 9-13,

413, 422, 423 thymosin fraction V therapy,

9-13 N,N-Dimethylamino-2-propanol,

331 DLE, see Leukocyte extract,

dialyzable DNA, see Deoxyribonucleic acid Dog

anaplastic mammary adenocarcino­ma, 229-247

therapy, 229-247 Doxorubicin, 232, 318 Ductal cell carcinoma, 240

EAC rosette, 376-377 EAG rosette, 376 Ear-swelling test, 123, 127, 128,

332

450

EHNA, see Erythro-9-(2-hydroxy-3-nonyl)-adenine hydro­chloride

Encephalitis, viral, acute, 367 Forest Spring -, 340 and isoprinosine therapy, 369

Encephalomyelitis, allergic, ex­perimental, 319

Encephalomyocarditis virus, 163, 340, 366

Endotoxin, 213-214, 220 immunostimulation by, 217

Enterotoxin, 214 Eosinophil

chemotaxis, 377-378 cytotoxicity, 381, 383

assay, 377 in parasite infection, 378-383 rosette formation, 376-377 separation, 376 stimulation in vitro, 378

Eosinophilia, 201-202 in filariasis, 376 in helminthiasis, 201 in hookworm disease, 376 in hypergammaglobulinemia, 202 in schistosomiasis(bilharzia-

sis), 376 in trichinosis, 201, 376

Epstein-Barr virus, 163, 165, 170, 181

in malignant lymphoma, 294 E-rosette, 35, 38, 40, 43, 50,

57, 61, 69, 72, 73, 75, 76, 81, 306, 307

assay, 70 Erythroblastopenia

infantile, 429, 431 transient, infantile, 429

Erythrocyte of sheep, 3 Erythro-9-(2-hydroxy-3-nonyl)­

adenine hydrochloride (EHNA), 258

Erythropoietin autoantibody against, 429

Escape mechanism for parasite, 198-199

by immunomodulation, 198-199 by mimicry, molecular, 198-199 by seclusion, anatomical, 198

INDEX

Escape mechanism for parasite (continued)

by variation, anti·senic, 198 Escherichia coli, 138, 214, 215

enterotoxin, 214 E-SRFC, see E-sheep ·rosette E-sheep rosette forming cell,

9

Fasciola hepatica, 203 5-Fluorouracil, 232, 242, 250,

252 Fluoxymesterone, 232 Forest-Spring encephalitis, 340 Friend leukemia virus, 155, 163,

181, 219 Freund adjuvant, 212

Gallium, 37 Globulin, antithymocyte, 400 Glucocorticoid

immunomodulation by, 269-277 immunosuppression by, 269 and T-lymphocyte mitogenesis,

269-277 Goat antiserum polyvalent, 70 Gold therapy in arthritis, 371 Gout, 372 Graves' disease, 411

Hamster as model, 12.3-128 Hashimoto's disease, 411 Helminthiasis, 201, 376 Helper T-cell, 279-292

limiting dilution system for, 282

Hemocyanin, 106 Hepati tis, 181 Hepatitis virus,

A, 163 B, 163 murine, 163

Herpes cutaneous, 369 Herpes genitalis, 367

and methisoprinol therapy, 387, 390-392

Herpes labialis, 305 and methisoprinol therapy,

386-390, 393 Herpes saimiri virus, 178

INDEX

Herpes simplex virus, 163, 183, 333, 334, 341

Herpes zoster, 344, 369 Histocompatibility complex, ma­

jor(MHC), 5, 7 HLA antigen, 5 Hodgkin's disease

E-rosette assay, 70, 81 histopathology of, 70 immunology of, 69 and laparotomy, 70 and leukocytes, 71 and lymphocytes, 70-72 and platelet, 71, 76 staging, 70 and thymostimu1in, 69-83

Hormones, see individual hormone Horseradish peroxidase method,

239 Host-parasite relationship, 197-

208 HTL, see Helper T-cell Hypergammag1obu1inemia, 35, 199-

201 congenital, 185 and immunoglobulin E, 202 variable, 413, 416, 417, 421,

423 Hypersensitivity, delayed, 318

assay, 123 Hypogammag1obu1inemia, common

variable, 11

Ia antigen, 407-412 ID disease, see Immunodeficiency

disease Immune response

afferent arm, 210 antigen

processing, 210 recognizing, 210

efferent arm, 210 impairment, listed, 304 and parasites, 197-208 and tumor, 18

Immunity concomitant, 198 effective, 198 non-sterilizing, 198

Immunoabsorbent assay, 71

Immunocyte classes, 164-165

451

and viruses, 165-173 destiny inside of, 171-

173 invasion by virus, mechanism,

175-177 immunomodu1ation, 177-182

persistence of virus within, 174

virus infection, 180, 182 changes after, 173-175

Immunodeficiency, 304, 305 disease, 5-15, 413-425

T-cell imbalance, 417 therapy with thymic hormone,

7-15 thymic epithelial cell, 5-7

patien t with, 5 severe combined(SCID), 9, 331

Immunodepressant, cytolytic, 318 Immunodepression, virus-induced,

184 Immunoglobulin

E hypersyndrome, 11-13 secretion assay, 259-260

Immunomodu1ation, ~09-228, 269-277, 311-329, 349-361

by basteria antigen, 209-228 by cyclophosphamide, 349-361 by glucocorticoid, 269-277 by interferon, 155-159 by inter1eukin I, 269-277 mechanisms, listed, 315 and virus infection, 161-195 by xenobiotics, 311-329

Immunoparasitosis, 197-208 Immunopotentiator, 185 Immunostimu1ation by endotoxin,

217 Immunosuppression

mechanisms, listed, 203 and parasites, 202-203

Immunotoxico1ogy, 311-319 classification, 312-314 definition, 312-314 mechanisms, listed, 315 realm of, 311 screening for, 314-318 substances, listed, 315

452

Immunotoxicology, (continued) testing, 318-325 xenobiotics, listed, 315

Infection, viral, 161-195 immune function suppressed,

mechanisms of, 183-185 substances

produced, 180-181 released, 180-181 see Immunomodulation, Inter­

feron and thymostimulin, 17-33

Influenza virus, 183, 333, 334, 338, 341, 343, 366

challenge and isoprinosine, 369 Ionsine, 331-333 Inosine monophosphate, 331 Inosiplex, see Isoprinosine,

Methisoprinol Interferon, 18, 24, 250, 340,

341, 366 antitumor agent, 155-159 antiviral state established,

133-138 enzyme, effects on

depression, 135 synthesis, 134

host immune system, 136 protein synthesis, 134-135

clinical use in the future, 138-140

and Corynebacterium parvum~ 213

discovery(1957), 131 diseases, human, potential use

for, listed, 139 effects listed, 132 and enzyme

depression, 135 synthesis, 134

host immune system, 136 immune -, 18 immunomodulator, 155-159 in leukemia, 135 lymphoblastic, 254 in medicine, 131-154 from Namalwa strain of lympho­

blast, 254 in physiology. 131-154 recombinant leukocyte A - 254

INDEX

Interferon (continued) use, potential, in human disease,

listed, 139 and virus infection in mouse,

26-27 Interleukin I, 107, 108, 109,

213, 214, 223, 269-277, 279-280, 298, 338

and T-cell lymphocyte mitogene­sis, 269-277

Interleukin-2, 279-292, 363, 365 Interleukin

concept, 279-280 model, 279

Isograft in mouse, 89-91 Isoprinosine, see Methisoprinol

(two names for the same compound)

Japan and cancer therapy, 249-256 list of agents used, 250

Kaplan-Meier method. 252 Keyhole limpet hemocyanin, 106 Klebsiella sp. 212 Krestin, 250

from Coriolus ve~sicolor str. CMlOl, 250, 251

Lactate dehydrogenase virus, 163 Lectin, 107 Leishmania~ visceral, 199, 200 Lentinan, 250

from Lentinus edodes for cancer therapy, 251

Lentinun edodes mushroom for cancer therapy, 250, 251

Leukemia, 344 and interferon, 155

Leukemia virus, murine, 163 Leukocyte

adherence inhibition assay, 123 of cord blood of neonate, 106,

110 extract, dialyzable(DLE), 105-

114 in animal model, 123-128 and cell-mediated immunity

in patient, 105 and CM virus donor, 107

INDEX

Leukocyte (continued) extract, dialyzable(DLE), (con­

tinued) transfer factor activity,

105-106 a complex mixture of 200

moieties, 120 guidelines for clinical

use, 118 immunoprophylaxis, 118 migration inhibition

factor, 106 test, 106, 119-123

Levamisole, 250, 303-309, 371, 372

in cancer therapy, 254, 305-306

in herpes labialis, 305 properties, 303 in rheumatoid arthritis, 305 treatment guidelines for, 307 use, clinical, 304-307

Lewis lung carcinoma(3LL), 19-24, 89-90

cells as inoculum, 19, 20 and nitrosourea, 19 TS treatment, 19-22

Lipid A, 213 Lipopolysaccharide, bacterial,

213, 215-222, 258, 295, 319, 333, 334, 338

Lipoteichoic acid, 215-222 immunostimulation by, 217 from streptococcus faecalis~

216 Listeria monocytogenes~ 338, 366 LMS, see Levamisole Lomustine, 19 Lupus erythematosus, systemic,

411 Lymphob las t, 4 Lymphocyte

activating factor, 214 activation, 107 adenosine and function, 257-

267 antibody, monoclonal, against,

414 bare lymphocyte syndrome, 7 B-cell, 5-6, 210

Lymphocyte (continued) B-cell (continued)

activation, 261-264 assay, 414 differentiation, 414 function, 257-267 suppressor activity, 414 T-cell interaction, 5

453

decrease in metastatic patient, 44-48

deoxyadenosine and function, 257-267

differentiation, 1-8 E-rosette assay, 70 function and

adenosine, 257-267 deoxyadenosine, 257-267

of Hodgkin's disease patient, 70, 72

isolation, 414 and isoprinosine, 367 microtoxicity test, 43 migration index, 71 mitogenesis, 269-277 of peripheral blood(PBL), 257-

258, 270, 414 and phytohemagglutinin trans­

formation, 70-72, 76 stimulation index, 71 surface

antigen, 407-412 marker, induction of, 1-4

T-cell, 210 activation, 260-261 antibody, monoclonal, 399-406 -B-cell interaction, 5 cytofluorometry, 410 cytolysis, 279-292 cytotoxicity, 18, 183, 279-

292, 340 function, 257-267

restored, 12-13 growth factor, 269 responder cell, 279-292

sensitized, 279 subpopulations, 279

transformation, 34, 70-72, 76 X antigen recognition, 6

Lymphocytic choriomeningitis virus, 163

454

Lymphoid cell, 349 and leukin-2 activity, 285

Lymphokine, 18, 107, 119, 131, 296-298, 365

cytotoxicity, 298 and tumor cell, 298

Lymphoma, malignant and Epstein-Barr virus, 294

Lynestrenol, 319 Lysozyme of serum, 71-72, 80 Lytic unit, defined, 24

Macrophage, 18, 24, 85, 210, 269, 273, 320

activating factor, 296 RNA, 85

Malaria, human, 200 MBP, see Protein, major basic MDP, see N-Acetyl-muramyl-L-ala-

nyl-d-isoglutamine Measles

disease, 184, 305 virus, 170

Megestrol acetate, 232 Melanoma, 92, 93, 98

and cell-mediated immunity, 43 fall in lymphocytes, 44-48 isograft, 89 and metastasis, 44-52, 58-59,

61, 63 and mitogen, 43 lymphocyte decline, 44-48 and rosette formation, 43, 57 and T-cell subsets, 48-52 and thymostimulin, 43-67

Melphalan, 232 Membrane immunofluorescence, 70 Mengovirus, 24-27 Mesocestoides, 200 Mestranol, 319 Methisoprinol, 363-374, aeg 1so­

prinosine antiviral, 333, 363, 385 in arthritis, rheumatoid, 370-

371 hypothesis, 372

biological activity, 332 in burned patient, 376 and cancer, 343 cell response to, 336-341

INDEX

Methisoprinol (continued) clinical use of, 333, 343-344

results, 368-372 in cytomegalovirus infection,

370 in encephalitis, acute, viral,

369 in herpes

cutaneous, 369 genitalis, 386, 387, 390-392 labialis, 386-390, 393 zoster, 369

and immune system, 364 and immunocompetence, 343 immunoglobulin 11 production,

366 immunopharmacology, 331-348 influenza challenge, 369 an inosine complex, 331, 332 mitogen response increased, 364 in panencephalitis subacute,

sclerosing, 368-369 pharmacology, 36q· potentiation by, 336 properties, immunological, 364-

368 posology, 368 purine degradation incomplete,

372 response, proliferative, listed,

334 side effects, 364 in stomatitis, aphthous, 369,

386, 394 T-cell macrophage activity in­

creased by, 363, 366 in upper respiratory infection,

376, 391-393, 395 and virus

infection, 375-384 therapy, 385-397

and warts, 369 Methotrexate, 232 20-Methylcholanthrene, 18

skin cancer in mouse, 18 MHe, see Histocompatibility com-

plex, major Microtoxicity test, 43 Migration index, 71 Mimicry, molecular, 198

INDEX

Mitogen, 4, 43, 258, see individ-ual mitogen

Mitogenesis, 269-277 Mitogenicity, 200, 217 Mitomycin C, 250, 252 Moloney leukemia virus, 18 Momordica charantia

plant toxin, 324, 326 protein, 324

Monocyte, 269, 273 Monokine, 213, 214 Mouse

cell line L929, 25 YAC-l, 25

strain C57BL/6, 24, 27 ICR, 24, 27

tumor-bearing and thymostimu­lin, 18-24

virus-infected, 23-26 MP virus, see Choriomeningitis,

lymphocytic, virus Mucopeptide, 252 Multiple sclerosis, 137 Muramylpeptide, 213 Mushroom polysaccharide in cancer

therapy, 250 Mycobacteriwn sp.

cord factor, 212 M. bovis, 296, see Bacillus

Calme t te-Gm~ rin M., fortuitwn, 116-117

Mycolic acid, 213 Myelopathy, autoimmune, 427-434

disorder, clinical anemia, aplastic, 430 aplasia, 429, 430 erythroblastopenia, 429 neutropenia, 430 thrombocytopenia, 430

list of, 431 mechanism, pathogenic, 428 and stem cell immunology, 427-

428

Natural killer cell, 10, 18, 23, 24, 26, 28, 213, 320, 340

function, 414, 416, 417, 422

455

Nematospiroides sp., 200 Neutropenia, autoimmune, central,

430 Newcastle disease virus, 163 Nippostrongylus brasiliensis,

200 Nitrosourea, 19 Nocardia rubra cell-wall skeleton

in cancer therapy, 250, 252 Nocardomycolic acid, 252 Norethindrone, 319 Norethynodrel, 319 Nucleoside phosphorylase, 331

Ochratoxin, 324 OKT, see Antibody, monoclonal Onchocerca volvulus, 202 Osteosarcoma, 123

and DLE therapy, 123-125

Panencephalitis, subacute, sclerosing, 343, 368-369

isoprinosine therapy, 369 Paracrine secretion, defined, 140 Parainfluenza virus, 185 Parasite

-host relationship, 197-208 infection and immune response,

375-376 Parasitosis

eosinophilia in, 201-202 escape mechanism for parasite,

198-199 hypergarnnaglobulinemia, 199-

201 immune response in, 197-198 immunomodulation, 197-208 immunosuppression, 202-203 and life cycle of parasite, 199

Penicillamine, 371 Peptidoglycan, 211, 212 Pertussis toxin, see Bordetella

pertussis Phagocytosis, 448, 340, 366 Phytohemagglutinin, 12, 23, 43,

69, 70-72, 76, 258, 259, 270-276, 295, 296, 333, 334, 338, 341, 364-367

Phytolacca americana plant toxin, 326

456

Phytolacca americana, (contin­ued)

protein, antiviral, 324 Pichinde virus, 181 Picibanil, 249-250

in cancer therapy and chemotherapy, 250 from streptococcus sp., 249-

250 Picryl chloride sensitivity, see

Ear-swelling test Plasma perfused over immobilized

protein A, 229-247 Platelet aggregation, 71, 79 Penumonia

bacterial, 181 viral, 181

Pokeweed mitogen, 258, 333, 334 Polysaccharide, pneumococcal,

212, 321 and immunoparalysis, 212 and tolerance, 212

PPD, see Protein, purified deriv­ative

Propylenglycol, 312 Prostaglandin

E, 180 F, 180

Protein A, staphylococcal, 211, 229-

247, 258 cytotoxicity, 229-247 properties listed, 230 and tumor regression, 229-247

major basic(MBP), 202 purified deri vati ve (PPD) ,43,

72, 78, 119, 125, 367 Protein kinase, 141 Protothymocyte, 1-4, 365

from bone marrow, 1-3 from spleen, 1

Purine metabolism and isoprino­sine, 372

Rabies, 183 in mouse, 179

Rauscher leukemia virus, 155 Renal cell cancer, metastatic,

93-96 Renal transplant patient, 399-

406

INDEX

Reovirus, 183 Respiratory infection, upper (URI)

methisoprinol therapy, 387, 391-395

Retrovirus, oncogenic, 162, 184 Rheumatoid arthritis, see Arthritis Rhinovirus, 341 Ricin, 324 RNA, immune, 85-104

cell-mediated immunity augmented by, 86

and cytotoxicity, 86 from immune donor, 88 for immune therapy in human can­

cer, 91-98 and infectivity of viral RNA,

85 and lymphoid cell entry

claimed (l96l), 88 confirmed (l964), 88

therapy with, 89 and tumor

immunity transfer, 85-104 -specific, 88

RNase, 89-92 Rosette formation, 2-,'1, 265, 376-

377 Rubella, 185

Saccharin bioavailability in humans, 325 and carcinogenicity, 323-324 and immunology, 320, 323 in rat, 325

Sarcoma, murine isograft outgrowth, 89 -l80, 366

Sarcoma virus, murine, 181 Schistosoma sp., 200, 203

S. mansoni~ 200, 202 SeID, see Immunodeficiency, severe

combined Scribner arterio-venous shunt, 94 Seclusion, anatomical, of a para­

site, 198 Serratia marcescens~ 215-223 Serum thymic factor(STF), see

Thymulin Sjorgren's syndrome, 39 Skin test reactivity, 106, 107

INDEX

Spleen cell, 215-222, 286, 289, 295,

296, 333, 356 natural killer cell, 23 phytohemagglutinin, 23 weight, 22-23

Splenocyte, 92, 93 staphyZococcus aureus

fractions, 211 protein A, 229-247, see Pro­

tein A strain, 233

Stem cell immunology, 427-428 lymphoid, 10 membrane antigen, 428

listed, 428 Steroid contraceptive drugs,

listed, 319 Stimulation index, 71 Stomatitis, aphthous, recurrent,

305, 369 and methisoprinol therapy, 388

streptococcus faecaZis~ 216 S. pyogenes preparation for

cancer therapy, 249-250 Streptokinase, 72, 78 streptomyces abivoreticuZi~ 253

bestatin from 253 Superinfection, 184

viral, 162 first reported (Z908) , 162,

164 Suppressor

assay, 4 T-cell as, 350

Tamoxifen citrate, 232 T-cell, see Lymphocyte T-cell Tegafur, 252 Teichoic acid, 211, see Lipo­

teichoic acid Tetanus toxoid, 333, 334 Tetramisole, 303

antihelminthic, 303 TFd, see Transfer factor, dialy-

zable Theta antigen, 39 ThF, see Thymic factor Thrombocytopenia, amegakaryotic,

430, 431

Thymic aplasia, 9 hypoplasia, 9

Thymic factor, 1-8, 17 effects, 1-5 in serum, 17 thymosin, 17 thymopoietin, 17 thymostimulin, 17 T-lymphocyte, human, 1-8

Thymic hormone, 17 synthetic, 10 therapy, 9-15

457

in primary immunodeficiency disease, 9-15

Thymocyte assay, 271 immaturity, 275 mitogenesis, 271 proliferation, 271

Thymopoietin, 2, 10, 17 therapy with, 10-11

Thymosin, 2, 17 fraction V, 9

Thymostimulin, 10, 17-33, 43-67 and cancer in model, 18-24 effects, 52, 56, 57, 72 and Hodgkin's disease, untreated,

69-83 and interferon production, 26 in melanoma patient, 43-52,

57-65 in patient, 57-61 properties, 17-18, 69 and skin test reactivity, 78 and tumor in mouse, 18-24 and virus infection, 23-26

Thymulin, 35-42 activity, biological, 38-39 analogue, 37 antibody, monoclonal, against,

37-38 biochemistry, 36-37 biological activity, 38-39 clinical trial, 39-40 marker induction, 39 properties, listed, 35 T-cell function, 35, 39 and therapy, 35 in thymus gland, localization of,

37-38

458

Thymulin (continued) and zinc, 35-37

Thymus gland, 17, 212 and cancer, 18 fetal, 4-5 and immunity, 69 T-lymphocyte, see Lymphocyte,

T-cel1 TP5, see Thymopoietin pentapep­

tide Transfer factor, 105~106

dialyzable, 120 Lawrence phenomenon, 115 leukocyte migration inhibition

assay for potency of, 119-123

potency, 115-130 prediction of clinical response

to, 115-130 test, 107-110

Transfer of immunologic informa­tion affecting the humor­al immune response achieved, 85

Transplant antibody

monoclonal, 399-406 renal, 399-406

immunosuppressive therapy, con-ventional, 400

of liver, 5, 6 and serum creatinine, 399 of thymus, 5

Transplantation immune respon­siveness

amplified by RNA, 85 Trehalose, 212 T-responder cell, see Lymphocyte TT'ichineZZa spiraZis, 201-203

model for immune response, 203-204

TT'ichode~a poZysporum, 293 cyclosporin A from, 293-302

T-rosette, 365 Trypanosoma cruzi, 202 Trypanosomiasis, African, 199 Tubercle bacillus, see MYcobac-

teT'ium sp. Tuberculosis, facial and DLE

therapy, 116

INDEX

Tumor cel1, 299 cytotoxicity against, 298-299 eradication by cyclophosphamide,

349-361 immunity, 18, 85-104

immune RNA, 85-104 transfer of, 85-104

MoPC-JZ5, 351-355, 360 remission in human, 229-246 thickness test, 46 and thymostimulin, 18-24

Variation, antigenic for escape of parasite, 198

Varicella zoster virus, 341 Vesicular stomatitits virus, 25,

163 VibT'io choZerae enterotoxin, 214 Vincristine, 232 Vinyl chloride a-thioglycerol, 312 Virus, see individual virus,

Immunocyte ~ Immunomodula­tion, Interferon

infection, 161-195 Viruxan, see Methisoprinol

Wart, 369-370 and isoprinosine therapy, 369-

370 Willcoxon-Gehan test, 252 Winter illness of children, 305 Wiskott-Aldrich syndrome, 9

"x" antigen, 6 Xenobiotics

activity, immunological, 317 and immune system, 312 immunomodulation, 311-329 immunotoxic, list of, 315 listed, 315 testing approaches listed, 317

Yellow fever virus, 170

Zinc, 11-12, 35-37 Zymosan, 338